Teva

Twelve Israeli companies rose more than 100% on Wall Street in 2024.

The collaboration between the two companies reflects ongoing efforts to enhance drug development, the CEO of Immunai said.

The long-running case against Teva started with EU dawn raids in 2019 that led to the opening of an investigation in 2021.

After years of financial and legal problems, Israel’s Teva Pharmaceutical Industries Ltd. named No.19 among the world’s top 20 best-earning pharmaceutical companies.

Participants in the panel included Prof. Eilat Shinar (MDA), Talia Tzour Avner (JNF-USA), Amalia Adler-Waxman (Teva), Shari Mendes (Israel Lemonade Fund) and lawyer Ayelet Razin Bet Or.

Amalia Adler-Waxman, Senior Vice President, Global Head of Sustainability and Head of Corporate Affairs of International Markets at Teva, spoke at the Jerusalem Post's Women Leaders Summit.

The Teva company enlisted in the national mission and established "Mental Caregivers", a program to strengthen mental resilience.

They collected and shipped hundreds of laptops that had been previously used, now repurposed to aid those affected by the conflict.

Speaking at the Israel Summit, Dr. Eran Harary, a psychiatrist and a Senior Vice President at Teva's Global R&D, explained how Israelis can overcome the shock and find themselves more resilient.

Nevada, along with other states and thousands of local governments, accused Teva and other drugmakers of downplaying the addiction risks of opioid pain drugs.